Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead… - The Lancet …, 2016 - thelancet.com
Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …
被引用次数：140 相关文章
[HTML] nih.gov

[HTML][HTML] Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead… - The lancet …, 2016 - ncbi.nlm.nih.gov
Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …
[PDF] academia.edu

[PDF][PDF] Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead, BA Kidd… - Lancet, 2016 - academia.edu
Background—Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.

DM Ruderfer, AW Charney, B Readhead… - The lancet …, 2016 - europepmc.org
Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead, BA Kidd… - The Lancet …, 2016 - Elsevier
Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …

Polygenic overlap between schizophrenia risk and antipsychotic response: A genomic medicine approach

DM Ruderfer, AW Charney, B Readhead… - The Lancet …, 2016 - asu.elsevierpure.com
Background: Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead… - The Lancet …, 2016 - cdr.lib.unc.edu
Therapeutic treatments for schizophrenia do not alleviate symptoms for all patients and
efficacy is limited by common, often severe, side-effects. Genetic studies of disease can …

[引用][C] Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead, BA Kidd… - The Lancet …, 2016 - cir.nii.ac.jp
Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic
medicine approach | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …
[PDF] core.ac.uk

[PDF][PDF] Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney, B Readhead, BA Kidd… - Lancet, 2016 - core.ac.uk
Background—Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …

Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach

DM Ruderfer, AW Charney… - The lancet …, 2016 - pubmed.ncbi.nlm.nih.gov
Background Therapeutic treatments for schizophrenia do not alleviate symptoms for all
patients and efficacy is limited by common, often severe, side-effects. Genetic studies of …